ValuEngine upgraded shares of Quotient (NASDAQ:QTNT) from a hold rating to a buy rating in a report published on Friday.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Quotient from a sell rating to a hold rating in a research note on Wednesday, October 10th. BidaskClub raised shares of Quotient from a sell rating to a hold rating in a research note on Tuesday, October 2nd.
QTNT traded up $0.49 during trading on Friday, hitting $6.88. The stock had a trading volume of 172,278 shares, compared to its average volume of 190,312. The stock has a market capitalization of $320.56 million, a P/E ratio of -3.41 and a beta of 0.45. Quotient has a twelve month low of $2.78 and a twelve month high of $9.02.
Quotient (NASDAQ:QTNT) last announced its quarterly earnings data on Monday, November 5th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $6.25 million for the quarter, compared to the consensus estimate of $5.80 million. On average, sell-side analysts anticipate that Quotient will post -1.92 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in QTNT. Perceptive Advisors LLC increased its stake in Quotient by 35.6% in the 3rd quarter. Perceptive Advisors LLC now owns 8,789,054 shares of the company’s stock valued at $66,357,000 after buying an additional 2,306,034 shares during the period. Highbridge Capital Management LLC increased its stake in Quotient by 2,558.7% in the 3rd quarter. Highbridge Capital Management LLC now owns 2,036,337 shares of the company’s stock valued at $15,375,000 after buying an additional 1,959,746 shares during the period. Millennium Management LLC acquired a new position in Quotient in the 2nd quarter valued at $3,699,000. Bellevue Group AG grew its stake in shares of Quotient by 125.7% during the 3rd quarter. Bellevue Group AG now owns 721,858 shares of the company’s stock worth $5,450,000 after purchasing an additional 402,044 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in shares of Quotient during the 2nd quarter worth $3,179,000. 48.80% of the stock is currently owned by institutional investors.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Story: Moving Average (MA)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.